
    
      The study is a single-arm, prospective, open-label, phase II study to observe the efficacy
      and safety of niraparib combined with bevacizumab in the treatment of FIGO III/IV platinum
      refractory/resistant ovarian cancer, fallopian tube cancer and primary peritoneal cancer.The
      primary end point is the objective response rate, and the secondary end points are
      progression free survival, duration of remission, disease control rate and safety. We also
      stratified analysis the level of tumor load, the status of BRCA and HRD on the efficacy and
      safety.
    
  